Korean J Dermatol.
2008 Oct;46(10):1435-1438.
A Case of Drug Eruption with Localized ExfoliativeDermatitis Induced by Imatinib Mesylate
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Chung-Ang University, Seoul, Korea. drseo@hanafos.com
Abstract
- Imatinib mesylate (Gleevec(R), formerly known as STI571) is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase created by the Philadelphia chromosome abnormality in patients with chronic myeloid leukemia (CML). Between 7 to 21% of the patients treated with imatinib mesylate have been reported to develop adverse cutaneous reactions. However, exfoliative dermatitis related to imatinib mesylate is rare and there is only one previously reported case of this in the Korean literature. We report here on a woman with localized exfoliative dermatitis that developed after administering imatinib mesylate for treating her CML.
MeSH Terms
-
Benzamides
Dermatitis, Exfoliative
Drug Eruptions
Female
Fusion Proteins, bcr-abl
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mesylates
Philadelphia Chromosome
Piperazines
Protein-Tyrosine Kinases
Pyrimidines
Imatinib Mesylate
Benzamides
Fusion Proteins, bcr-abl
Mesylates
Piperazines
Protein-Tyrosine Kinases
Pyrimidines
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Lichenoid Drug Eruption Associated with Imatinib Mesylate
- A Case of Psoriasiform Drug Eruption Induced by Imatinib Mesylate (GleevecTM)
- Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec(TM))
- Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
- Imatinib Mesylate (Gleevec(TM))-induced Lichenoid Drug Eruption Improved by Tentative Dose-reduction and Topical Steroid
